Povetacicept

Vertex Pharmaceuticals · ALPN-303

FollowEvery change as it happens, and a Monday email
Stage
in the US · press release
Next date
Phase 3 trial completes
Trials
6 active
9 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
BAFF/APRIL dual inhibitor (TACI-Fc fusion protein)
How it’s given
“Placebo matched to Povetacicept subcutaneous injection administration.”In the company’s words, NCT06564142 on ClinicalTrials.gov
Tested for
Immunoglobulin A Nephropathy (4 trials), Primary Membranous Nephropathy, Myasthenia Gravis, Generalized, Lupus Nephritis, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Main trialPhase 3
“The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the safety and tolerability of Povetacicept in participants with Immunoglobulin A nephropathy (IgAN).”In the company’s words, NCT07890909 on ClinicalTrials.gov
Other names
ALPN-303

Other drugs for Immunoglobulin A Nephropathy

All 39 drugs for Immunoglobulin A Nephropathy

Coming up6

Changes2

Last 90 days

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 12 Dec 2027 A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
Phase 3Active, not recruiting 30 Jan 2028 Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
Phase 3Enrolling by invitation 28 Dec 2029 A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Phase 2/3Recruiting 27 Jun 2029 Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Phase 2Active, not recruiting 2 Mar 2029 A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Phase 1/2Active, not recruiting 2 Mar 2028 An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Phase 1/2Completed 12 Aug 2026 An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
Phase 1Completed 27 Feb 2023 A Study of ALPN-303 in Adult Healthy Volunteers
Phase 1Completed 19 Aug 2025 A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Povetacicept

Following is part of Solo: you see every change to Povetacicept the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in